Phase II-HNSCC
Phase 2Small molecule
Phase II-HNSCC is one of 92 small molecule programs targeting Lymphoma. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
91
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
370 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Zofran
NovartisPreclinical
Cabenuva
GSKPreclinical
Phase II-HNSCC
SSuzhou Genhouse Bio Co., Ltd.
Phase 2
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Phase II-HNSCC. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSuzhou Genhouse Bio Co., Ltd.